Rybelsus contains semaglutide, a component known for its effectiveness in weight loss and classified as a GLP-1 receptor agonist.
While most GLP-1 receptor agonists are administered via injection to deliver GLP-1, Rybelsus is notable for its oral administration capability.
It not only stimulates insulin secretion to lower blood glucose levels but also regulates gastrointestinal movement, thereby suppressing appetite. Due to its ability to lower blood glucose levels, it is used as a treatment for type 2 diabetes.
Rybelsus tablets obtained manufacturing and marketing approval domestically on June 29, 2020, and were listed under the drug price standard on November 18 of the same year.
Source: Ministry of Health, Labour and Welfare “Regarding Newly Approved Drugs”
Active Ingredient | Semaglutide (genetically modified) 3mg per tablet |
Additives | Sodium salcaprozate, Povidone, Microcrystalline cellulose, Magnesium stearate |
Active Ingredient | Semaglutide (genetically modified) 7mg per tablet |
Additives | Sodium salcaprozate, Povidone, Microcrystalline cellulose, Magnesium stearate |
Active Ingredient | Semaglutide (genetically modified) 14mg per tablet |
Additives | Sodium salcaprozate, Povidone, Microcrystalline cellulose, Magnesium stearate |
The GLP-1 in Rybelsus promotes insulin secretion, which helps control blood glucose levels and suppresses appetite. Therefore, what is commonly referred to as the “GLP-1 diet” involves using medications that utilize the hormone GLP-1 for weight loss.
GLP-1 not only promotes insulin secretion to control blood glucose levels and suppress appetite, but it also controls gastrointestinal function. By slowing down the movement of the digestive tract, the digestion speed of food decreases, allowing you to feel full with a smaller amount of food.
Additionally, it slows down the absorption of food, which in turn slows down the absorption of sugars. This prevents a rapid rise in blood glucose levels after eating and helps reduce postprandial hyperglycemia. These mechanisms help suppress appetite.
Rybelsus is a type of medication known as a GLP-1 receptor agonist. GLP-1 receptor agonists are drugs that mimic the action of the hormone GLP-1.
The GLP-1 hormone present in the body is secreted from the small intestine when blood glucose levels rise after eating, promoting insulin secretion from the pancreas. When the amount of insulin increases due to the action of GLP-1, the amount of sugar in the blood decreases, which lowers blood glucose levels and makes it easier for cells such as muscle cells to use sugar as an energy source.
By utilizing this mechanism, it becomes easier to consume sugar. Moreover, Rybelsus is thought to help aim for a body constitution that burns calories more easily.
GLP-1 receptor agonists are mostly administered via injection to deliver GLP-1, but Rybelsus can be taken orally.
Rybelsus is available in 3mg, 7mg, and 14mg doses. We will consult with you to adjust the dosage as needed while you are taking the medication.
It controls the function of the gastrointestinal tract, making it easier to feel full with less food than usual.
It also acts on the satiety center to reduce hunger and suppress appetite.
Furthermore, it slows down the rate at which food is absorbed, gradually decreasing the absorption of sugars.
This prevents a rapid rise in blood sugar levels after meals and helps reduce postprandial hyperglycemia.
The GLP-1 hormone, which naturally exists in our bodies, is secreted from the small intestine when we eat and blood sugar levels rise, prompting the pancreas to release insulin.
Through the action of GLP-1, which increases the amount of insulin, the level of sugar in the blood decreases, leading to a reduction in blood sugar levels.
Utilizing the principle that cells in muscles and elsewhere can more easily consume sugar as an energy source, Liberthas targets GLP-1.
If you feel like you are eating the same amount as when you were younger but have become more prone to gaining weight and find it harder to lose weight, it may be due to changes in the function of fat cells due to aging.
Fat cells include “white fat cells” that store visceral and subcutaneous fat, and “brown fat cells” that burn fat. The active functioning of brown cells makes the body more capable of burning calories. However, the activity of brown fat cells declines with aging and obesity.
This means that as you age, the number of brown fat cells decreases and the amount of visceral fat increases due to obesity, leading to a reduced capacity of brown fat cells that should ideally be burning fat.
As you age, even if you eat the same amount as when you were younger, the reduction in number and activity of brown fat cells makes it harder for your body to burn calories.
Liberthas targets the functioning of these brown fat cells, making it easier to achieve a body that can readily burn calories.
Moreover, Liberthas is considered a medication with a higher weight loss effect compared to Saxenda.
Precautions | The following individuals are not eligible to take medication: Pregnant women, breastfeeding mothers, those planning to become pregnant Individuals with a history of pancreatitis Those currently taking other diabetes treatment medications orally or by injection |
---|---|
Risk of side effects | Please remove the tablet from the aluminum foil just before taking Liberasus. Due to its sensitivity to moisture and light, storing the tablets exposed may prevent the medication from working effectively. To ensure the medication works properly, avoid splitting or crushing the tablets before taking them. Doing so may not only reduce the effectiveness of the medication but could also increase the risk of side effects. |
Please feel free to contact us.